Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-28
2011-06-28
Loewe, Sun Jae Y (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S379100
Reexamination Certificate
active
07968582
ABSTRACT:
The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.
REFERENCES:
patent: 5017596 (1991-05-01), Colombo et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5849931 (1998-12-01), Frigola-Constansa et al.
patent: 6118009 (2000-09-01), Torrens-Jover et al.
patent: 6187930 (2001-02-01), Torrens-Jover et al.
patent: 6410582 (2002-06-01), Merce-Vidal et al.
patent: 6476060 (2002-11-01), Lange et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6610737 (2003-08-01), Garzon et al.
patent: 6956033 (2005-10-01), Ogawa et al.
patent: 7138424 (2006-11-01), Barth et al.
patent: 2002/0058816 (2002-05-01), Kordik et al.
patent: 2002/0156104 (2002-10-01), Adams et al.
patent: 2003/0022925 (2003-01-01), Merce-Vidal et al.
patent: 2003/0153569 (2003-08-01), Adams et al.
patent: 2004/0092535 (2004-05-01), Barsanti et al.
patent: 2004/0248944 (2004-12-01), Kruse et al.
patent: 2005/0137251 (2005-06-01), Garzon et al.
patent: 2005/0171179 (2005-08-01), Lange et al.
patent: 2005/0222138 (2005-10-01), Ohhata et al.
patent: 2005/0282798 (2005-12-01), Lazzari et al.
patent: 2006/0015198 (2006-01-01), Okabayashi et al.
patent: 2006/0020010 (2006-01-01), Altisen et al.
patent: 2006/0052315 (2006-03-01), Leung et al.
patent: 2006/0106014 (2006-05-01), Boddupalli et al.
patent: 2006/0128673 (2006-06-01), Firnges et al.
patent: 2006/0172019 (2006-08-01), Ralston et al.
patent: 2006/0189658 (2006-08-01), Altisen et al.
patent: 2006/0194843 (2006-08-01), Berdini et al.
patent: 2007/0015810 (2007-01-01), Cuberes
patent: 2007/0015811 (2007-01-01), Cuberes
patent: 2007/0021398 (2007-01-01), Torrens et al.
patent: 2007/0066651 (2007-03-01), Cuberes-Altisen et al.
patent: 2007/0073056 (2007-03-01), Torrens et al.
patent: 2007/0254862 (2007-11-01), Antel et al.
patent: 2008/0015198 (2008-01-01), Cuberes-Altisen et al.
patent: 3540934 (1987-05-01), None
patent: 1384477 (2004-01-01), None
patent: 1 209 326 (1970-10-01), None
patent: 02 117 605 (1988-10-01), None
patent: 8805046 (1988-07-01), None
patent: WO 88/05046 (1988-07-01), None
patent: WO 88/06583 (1988-07-01), None
patent: WO 92/03421 (1992-03-01), None
patent: WO 00/76503 (2000-12-01), None
patent: 0170700 (2001-06-01), None
patent: WO 02/080909 (2002-10-01), None
patent: 03026647 (2003-04-01), None
patent: 03097597 (2003-11-01), None
patent: WO 2004/060882 (2004-07-01), None
patent: WO 2004/078261 (2004-09-01), None
patent: 2005012256 (2005-02-01), None
patent: 2006045799 (2006-05-01), None
patent: WO 2006/077414 (2006-07-01), None
patent: WO 2006/077419 (2006-07-01), None
patent: WO 2006/077425 (2006-07-01), None
patent: WO 2006/077428 (2006-07-01), None
http://mojo.calyx.net/˜olsen/MEDICAL/IOM/iom115054635.html (25 pages).
http://www.norml.org/index.cfm?Group—ID=7282&wtm—format=print (2 pages).
http://www.nlm.nih.gov/medlineplus/ency/article/001553.htm (3 pages).
http://www.webmd.com/diet/tc/Obesity-Overview (3 pages).
http://health.yahoo.com/topic/addiction/abuse/article/pt/Psychology—Today—articles—pto—term—alcohol (6 pages).
Megard et al., “A co-culture based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation”, Brain Research, 927, 2002, 153-167.
Fact sheet Alzheimers association, 2 pages.
http://www.mayoclinic.com/health/alzheimers-disease/DS00161/DSECTION=3.
http://www.medindia.net/patients/patientinfo/Alzheimers—treatment.htm.
Zips et al, “new anticancer agents: in vitro and in vivo”, in vivo, 2005, 19, 1-7.
Chawla et al., “Challenges in Polymorphism of Pharmaceuticals”, CRIPS vol. 5, No. 1, Jan.-Mar. 2004 (**4 PAGES**.
Newman et al., “Solid-state analysis of the active pharmaceutical ingredient in drug products”, DDT vol. 8, No. 19, Oct. 2003, p. 898-905.
Antel et al., caplus an 2007:1278230.
Buschman et al., caplus an 2007:175440.
Buschman et al. 2, caplus an 2007:173847.
Buschman 3, caplus an 2007:88351.
http://mojo.calyx.net/˜olsen/MEDICAL/IOM/iom115054635.html (25 pages) 2007.
http://www.norml.org/index.cfm?Group—ID=7282&wtm—format=print (2 pages) 2007.
http://www.nlm.nih.gov/medlineplus/ency/article/001553.htm (3 pages) 2007.
http://www.webmd.com/diet/tc/Obesity-Overview (3 pages) 2007.
http://health.yahoo.com/topic/addiction/abuse/article/pt/Psychology—Today—articles—pto—term—alcohol (6 pages) 2007.
Fact sheet Alzheimers association, 2 pages 2007.
http://www.mayoclinic.com/health/alzheimers-disease/DS00161/DSECTION=3 2007.
http://www.medindia.net/patients/patientinfo/Alzheimers—treatment.htm 2007.
Chan et al., “N-substituted Pyrazoline-type Insecticides”, ACS Symposium Series, No. 800, p. 144-155 (2002); Chem. Abstr. XP002335857.
Meier et al., “Insecticidal Dihydropyrazoles with Reduced Lipophilicity”, ACS Symposium Series, No. 504 p. 313-326 (1992); Chem Abstr. XP002335858.
Meyer et al., “1,5-Diaryl-2,3-pyrrolidinediones—Phenylhydrazine Derivatives”, Journal of Organic Chemistry, vol. 22: 1565-1567 (1957); Chem Abstr. XP002335859.
International Search Report mailed Jul. 29, 2005 in International Application No. PCT/EP2005/001659.
Kenji Tamura et al., “One-Pot Synthesis of Trifluoroacetimidoyl Halides”, J. Org. Chem. 1993, 58, 32-38.
Hollister, L. E., “Health Aspects of Cannabis,” Pharmacological Reviews, vol. 38, No. 1, pp. 1-20 (1986).
Murphy, L. et al., Consroe and Sandyk, “Potential Role of Cannabinoids for Therapy of Neurological Disorders,” pp. 459-524, CRC Press (1992).
Slavinska, V. et al, “New Way for the Preparation of 4-Phenyl-2-Oxobutyric Acid Ethyl Ester,” Synthetic Communications, 26(11), 2229-2233 (1996).
DuJardin, G. et al., “A Straightforward Route to E-γ-Aryl-α-oxobutenoic Esters by One-step Acid-catalysed Crotonisation of Pyruvates,” Synlett, No. 1, pp. 147-149 (2001).
Pascual, Alfons, “Synthese des 5-[(Acetylhydrazono)-(4-chlorphenyl)-methyl]thiophen-2-yl-esters der Trifluormethansulfonäure,” J. Prakt. Chem. 341, No. 7, pp. 695-700 (1999).
Lin, S. et al., “Regloselective Friedel-Crafts Acylation with Unsymmetrically Substituted Furandicarboxylic Acid Anhydride and Furan Acid Chloride: Syntheses of 4-Substituted 3-Arylcarbonyl-2-Phenylfuran and 3-Substituted 4-Arylcarbonyl-2-Phenylfuran,” Heterocycles, vol. 55, No. 2, pp. 265-277 (2001).
Rao, P. D. et al., “Rational Syntheses of Porphyrins Bearing up to Four Different Meso Substituents,” J. Org. Chem., 65, pp. 7323-7344 (2000).
Pearson, D.E. and Buehler, C.A., “Friedel-Crafts Acylations with Little or No Catalyst,” Synthesis, No. 10: October, pp. 533-542 (1972).
Ross, Ruth A. et al., “Agonist-Inverse agonist characterization at CB1and CB2cannabinoid receptors of L-759633, L759656 and AM630,” British Journal of Pharmacology 126, pp. 665-672 (1999).
Howlett, A.C. et al., “International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors,” Pharmacological Reviews 54:161-202 (2002).
Compton, David R. et al., “In-Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A): Inhibition of Δ9-Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity,” The Journal of Pharmacology and Experimental Therapeutics, vol. 277, No. 2, 277:586-594 (1996).
Woolfe G. et al., “The Evaluation of the Analgesic Action of Pethidine Hydrochloride (Demerol),” The Journal of Pharmacology and Experimental Therapeutics, vol. 80, pp. 300-307 (1944).
Desmedt L.K.C. et al. “Anticonvulsive Properties of Cinnarizine and Flunarizine in Rats and Mice,” Arzneim.-Forsch. (Drug Res.) 25, Nr. 9, pp. 1408-1413 (1975).
G. Colombo et al., “Appetite Suppression
Banner & Witcoff , Ltd.
Laborotorios Del Dr. Esteve, S.A.
Loewe Sun Jae Y
LandOfFree
5(S)-substituted pyrazoline compounds, their preparation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5(S)-substituted pyrazoline compounds, their preparation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5(S)-substituted pyrazoline compounds, their preparation and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707824